{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:14:08Z","timestamp":1790662448320,"version":"4.1.0"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271494"],"award-info":[{"award-number":["32271494"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly defined as non-alcoholic fatty liver disease (NAFLD), is a disorder marked by the excessive deposition of lipids in the liver, giving rise to a spectrum of liver pathologies encompassing steatohepatitis, fibrosis\/cirrhosis, and hepatocellular carcinoma. Despite the alarming increase in its prevalence, the US Food and Drug Administration has yet to approve effective pharmacological therapeutics for clinical use. MASLD is characterized by the accretion of lipids within the hepatic system, arising from a disarray in lipid provision (whether through the absorption of circulating lipids or\n                    <jats:italic>de novo<\/jats:italic>\n                    lipogenesis) and lipid elimination (via free fatty acid oxidation or the secretion of triglyceride-rich lipoproteins). This disarray leads to the accumulation of lipotoxic substances, cellular pressure, damage, and fibrosis. Indeed, the regulation of the lipid metabolism pathway is intricate and multifaceted, involving a myriad of factors, such as membrane transport proteins, metabolic enzymes, and transcription factors. Here, we will review the existing literature on the key process of lipid metabolism in MASLD to understand the latest progress in this molecular mechanism. Notably,\n                    <jats:italic>de novo<\/jats:italic>\n                    lipogenesis and the roles of its two main transcription factors and other key metabolic enzymes are highlighted. Furthermore, we will delve into the realm of drug research, examining the recent progress made in understanding lipid metabolism in MASLD. Additionally, we will outline prospective avenues for future drug research on MASLD based on our unique perspectives.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2023.1294267","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T01:48:35Z","timestamp":1701049715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":89,"title":["Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic"],"prefix":"10.3389","volume":"10","author":[{"given":"Guocheng","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenmei","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"05000","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","author":"Song","year":"2023","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/dom.15014","article-title":"Epidemiological characteristics and management of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis in China: a narrative review","volume":"25","author":"Lu","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","article-title":"The global burden of metabolic disease: data from 2000 to 2019","volume":"35","author":"Chew","year":"2023","journal-title":"Cell Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.32542","article-title":"NAFLD-related hepatocellular carcinoma: the growing challenge","volume":"77","author":"Shah","year":"2023","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/hep.32774","article-title":"Geographical similarity and differences in the burden and genetic predisposition of NAFLD","volume":"77","author":"Yip","year":"2023","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"154873","DOI":"10.1016\/j.metabol.2021.154873","article-title":"Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk","volume":"124","author":"van den Hoek","year":"2021","journal-title":"Metabolism"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"105739","DOI":"10.1016\/j.phrs.2021.105739","article-title":"Hepatic stellate cells role in the course of metabolic disorders development\u2014a molecular overview","volume":"170","author":"Bourebaba","year":"2021","journal-title":"Pharmacol Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"154770","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovic","year":"2021","journal-title":"Metabolism"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"155220","DOI":"10.1016\/j.metabol.2022.155220","article-title":"Nonalcoholic fatty liver disease and cardiovascular diseases: a Mendelian randomization study","volume":"133","author":"Peng","year":"2022","journal-title":"Metabolism"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s42255-021-00493-6","article-title":"Lipolysis: cellular mechanisms for lipid mobilization from fat stores","volume":"3","author":"Grabner","year":"2021","journal-title":"Nat Metab"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"106679","DOI":"10.1016\/j.phrs.2023.106679","article-title":"Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): a position paper from the international lipid expert panel (ILEP)","volume":"189","author":"Rizzo","year":"2023","journal-title":"Pharmacol Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.molmet.2019.05.002","article-title":"ABHD15 regulates adipose tissue lipolysis and hepatic lipid accumulation","volume":"25","author":"St\u00f6ckli","year":"2019","journal-title":"Mol Metab"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41575-019-0250-7","article-title":"Regulation of intestinal lipid metabolism: current concepts and relevance to disease","volume":"17","author":"Ko","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.cgh.2021.11.026","article-title":"Systematic review and meta-analysis: the role of diet in the development of nonalcoholic fatty liver disease","volume":"21","author":"Tsompanaki","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2337\/db12-1689","article-title":"FAT\/CD36: a major regulator of neuronal fatty acid sensing and energy homeostasis in rats and mice","volume":"62","author":"Le Foll","year":"2013","journal-title":"Diabetes"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","article-title":"CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis","volume":"69","author":"Zhao","year":"2018","journal-title":"J Hepatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"101428","DOI":"10.1016\/j.molmet.2021.101428","article-title":"CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing","volume":"57","author":"Zeng","year":"2022","journal-title":"Mol Metab"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1074\/jbc.RA120.012730","article-title":"Deletion of fatty acid transport protein 2 (FATP2) in the mouse liver changes the metabolic landscape by increasing the expression of PPAR\u03b1-regulated genes","volume":"295","author":"Perez","year":"2020","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11418-022-01647-w","article-title":"Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease","volume":"77","author":"Ran","year":"2023","journal-title":"J Nat Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2006.02.006","article-title":"Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis","volume":"130","author":"Doege","year":"2006","journal-title":"Gastroenterology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3892\/etm.2011.328","article-title":"Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease","volume":"2","author":"Higuchi","year":"2011","journal-title":"Exp Ther Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/hep.32538","article-title":"Intestinal peroxisome proliferator-activated receptor alpha-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis","volume":"77","author":"Yan","year":"2023","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.cmet.2021.09.010","article-title":"Molecular aspects of fructose metabolism and metabolic disease","volume":"33","author":"Herman","year":"2021","journal-title":"Cell Metab"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","article-title":"Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease","volume":"61","author":"Softic","year":"2016","journal-title":"Dig Dis Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e13733","DOI":"10.1111\/eci.13733","article-title":"De novo lipogenesis in non-alcoholic fatty liver disease: quantification with stable isotope tracers","volume":"52","author":"Belew","year":"2022","journal-title":"Eur J Clin Investig"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s42255-023-00786-y","article-title":"Physiological and pathological roles of lipogenesis","volume":"5","author":"Jeon","year":"2023","journal-title":"Nat Metab"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrendo.2017.91","article-title":"SREBP-regulated lipid metabolism: convergent physiology\u2014divergent pathophysiology","volume":"13","author":"Shimano","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"106786","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol Res"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/hep.32381","article-title":"Discovery of an insulin-induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory element-binding protein-mediated lipogenesis","volume":"76","author":"Jiang","year":"2022","journal-title":"Hepatology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2010.10.024","article-title":"Distinct regulation of adiponutrin\/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes","volume":"55","author":"Dubuquoy","year":"2011","journal-title":"J Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.bbalip.2018.02.003","article-title":"FTO promotes SREBP1c maturation and enhances CIDEC transcription during lipid accumulation in HepG2 cells","volume":"1863","author":"Chen","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1073\/pnas.0401516101","article-title":"Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis","volume":"101","author":"Iizuka","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1038\/s41467-018-04361-y","article-title":"The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity","volume":"9","author":"Bricambert","year":"2018","journal-title":"Nat Commun"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1172\/JCI41636","article-title":"The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans","volume":"122","author":"Benhamed","year":"2012","journal-title":"J Clin Invest"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/db06-0200","article-title":"Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob\/ob mice","volume":"55","author":"Dentin","year":"2006","journal-title":"Diabetes"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cmet.2017.12.016","article-title":"The small intestine converts dietary fructose into glucose and organic acids","volume":"27","author":"Jang","year":"2018","journal-title":"Cell Metab"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"154222","DOI":"10.1016\/j.metabol.2020.154222","article-title":"DDB1 E3 ligase controls dietary fructose-induced ChREBP\u03b1 stabilization and liver steatosis via CRY1","volume":"107","author":"Tong","year":"2020","journal-title":"Metabolism"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/hep.31897","article-title":"A systematic review of animal models of NAFLD finds high-fat, high-fructose diets Most closely resemble human NAFLD","volume":"74","author":"Im","year":"2021","journal-title":"Hepatology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/hep.31198","article-title":"Hepatic carbohydrate response element binding protein activation limits nonalcoholic fatty liver disease development in a mouse model for glycogen storage disease type 1a","volume":"72","author":"Lei","year":"2020","journal-title":"Hepatology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e003288","DOI":"10.1161\/CIRCGEN.120.003288","article-title":"Sugar-sweetened beverage consumption may modify associations between genetic variants in the CHREBP (carbohydrate responsive element binding protein) locus and HDL-C (high-density lipoprotein cholesterol) and triglyceride concentrations","volume":"14","author":"Haslam","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.molcel.2019.05.019","article-title":"HCF-1 regulates de novo lipogenesis through a nutrient-sensitive complex with ChREBP","volume":"75","author":"Lane","year":"2019","journal-title":"Mol Cell"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2021.11.009","article-title":"A new perspective on NAFLD: focusing on lipid droplets","volume":"76","author":"Scorletti","year":"2022","journal-title":"J Hepatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/hep.32324","article-title":"Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD","volume":"76","author":"Moore","year":"2022","journal-title":"Hepatology"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/liv.14309","article-title":"Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: a palmitate breath test study","volume":"40","author":"Naguib","year":"2020","journal-title":"Liver Int"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1136\/gutjnl-2012-302789","article-title":"Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease","volume":"62","author":"Croci","year":"2013","journal-title":"Gut"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.3390\/ijms19071893","article-title":"Insights into the role of PPAR\u03b2\/\u03b4 in NAFLD","volume":"19","author":"Chen","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41419-019-1458-8","article-title":"PPAR\u03b4 attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation","volume":"10","author":"Tong","year":"2019","journal-title":"Cell Death Dis"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3892\/ijmm.20.3.351","article-title":"Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease","volume":"20","author":"Kohjima","year":"2007","journal-title":"Int J Mol Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"11816","DOI":"10.1096\/fj.202000678R","article-title":"Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD","volume":"34","author":"Weber","year":"2020","journal-title":"FASEB J"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1053\/jhep.2002.32527","article-title":"Apolipoprotein synthesis in nonalcoholic steatohepatitis","volume":"35","author":"Charlton","year":"2002","journal-title":"Hepatology"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"10874","DOI":"10.7150\/thno.47037","article-title":"Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD\/NASH development","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1615\/CritRevOncog.2020035839","article-title":"Understanding the alterations in lipid metabolism in NAFLD progression: current trends and future directions","volume":"26","author":"Mungamuri","year":"2021","journal-title":"Crit Rev Oncog"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1021\/jm200304y","article-title":"Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins","volume":"54","author":"Kamisuki","year":"2011","journal-title":"J Med Chem"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1194\/jlr.M069583","article-title":"Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner","volume":"57","author":"Shao","year":"2016","journal-title":"J Lipid Res"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/jpet.108.139626","article-title":"Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals","volume":"326","author":"Hawkins","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.2337\/db13-0835","article-title":"Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity","volume":"63","author":"Zhao","year":"2014","journal-title":"Diabetes"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41574-021-00627-6","article-title":"The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases","volume":"18","author":"Malik","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"101196","DOI":"10.1016\/j.molmet.2021.101196","article-title":"Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction","volume":"48","author":"Gutierrez","year":"2021","journal-title":"Mol Metab"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial","volume":"2","author":"Kazierad","year":"2021","journal-title":"Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"100217","DOI":"10.1016\/j.jhepr.2020.100217","article-title":"Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis","volume":"3","author":"Shepherd","year":"2021","journal-title":"JHEP Rep"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1053\/j.gastro.2022.11.019","article-title":"Hepatocyte Kctd17 inhibition ameliorates glucose intolerance and hepatic steatosis caused by obesity-induced Chrebp stabilization","volume":"164","author":"Oh","year":"2023","journal-title":"Gastroenterology"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1172\/JCI87382","article-title":"MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling","volume":"126","author":"Ahn","year":"2016","journal-title":"J Clin Invest"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"42477","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"5682","DOI":"10.3390\/ijms20225682","article-title":"Gene expression profiles induced by a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) pemafibrate","volume":"20","author":"Sasaki","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12072-022-10453-1","article-title":"Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study","volume":"17","author":"Morishita","year":"2023","journal-title":"Hepatol Int"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2337\/dc21-1288","article-title":"Efficacy and safety of K-877 (pemafibrate), a selective PPAR\u03b1 modulator, in European patients on statin therapy","volume":"45","author":"Ginsberg","year":"2022","journal-title":"Diabetes Care"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"101006","DOI":"10.1016\/j.plipres.2019.101006","article-title":"ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review","volume":"77","author":"Feng","year":"2020","journal-title":"Prog Lipid Res"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0003-9861(69)90532-3","article-title":"Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase","volume":"135","author":"Watson","year":"1969","journal-title":"Arch Biochem Biophys"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.13973","article-title":"Effectiveness of herbal medicines for weight loss: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Maunder","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"100051","DOI":"10.1016\/j.crphar.2021.100051","article-title":"ATP citrate lyase inhibitor bempedoic acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score","volume":"2","author":"Sanjay","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.arteri.2021.09.004","article-title":"Bempedoic acid as a PPAR\u03b1 activator: new perspectives for hepatic steatosis treatment in a female rat experimental model","volume":"34","author":"Bentanachs","year":"2022","journal-title":"Clin Investig Arterioscler"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.apsb.2022.06.011","article-title":"Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia","volume":"13","author":"Xie","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat Med"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"eabg8117","DOI":"10.1126\/scitranslmed.abg8117","article-title":"Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"eabg8116","DOI":"10.1126\/scitranslmed.abg8116","article-title":"A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1128\/br.40.3.681-697.1976","article-title":"The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis","volume":"40","author":"Omura","year":"1976","journal-title":"Bacteriol Rev"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1073\/pnas.97.7.3450","article-title":"Synthesis and antitumor activity of an inhibitor of fatty acid synthase","volume":"97","author":"Kuhajda","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/s41564-023-01369-z","article-title":"Inhibiting fatty acid synthesis overcomes colistin resistance","volume":"8","author":"Carfrae","year":"2023","journal-title":"Nat Microbiol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2337\/diabetes.50.4.733","article-title":"Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting","volume":"50","author":"Makimura","year":"2001","journal-title":"Diabetes"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1073\/pnas.042683699","article-title":"Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice","volume":"99","author":"Kumar","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities","volume":"72","author":"Syed-Abdul","year":"2020","journal-title":"Hepatology"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/dom.14272","article-title":"Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: results from two early-phase randomized trials","volume":"23","author":"Beysen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2337\/db08-1074","article-title":"Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver","volume":"58","author":"Kotronen","year":"2009","journal-title":"Diabetes"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.cmet.2007.10.014","article-title":"Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis","volume":"6","author":"Miyazaki","year":"2007","journal-title":"Cell Metab"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"14859","DOI":"10.1038\/ncomms14859","article-title":"Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice","volume":"8","author":"Schweiger","year":"2017","journal-title":"Nat Commun"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s13238-017-0436-0","article-title":"New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"9","author":"Zhang","year":"2018","journal-title":"Protein Cell"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1294267\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T01:48:39Z","timestamp":1701049719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1294267\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":120,"alternative-id":["10.3389\/fmed.2023.1294267"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1294267","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"article-number":"1294267"}}